Skip to main content
Fig. 4 | Cardiovascular Diabetology

Fig. 4

From: Cardiovascular benefits of SGLT2 inhibitors in type 2 diabetes, interaction with metformin and role of erythrocytosis: a self-controlled case series study

Fig. 4

Forest plot of incidence rate ratios of study outcomes by exposure of metformin and SGLT2i. The incidence rate ratio of study outcomes between periods of (i) metformin use without SGLT2i; (ii) pre-SGLT2i (three months before each initiation of SGLT2i); (iii) SGLT2i use alone period; and (iv) combined use of metformin and SGLT2i period, were estimated using conditional Poisson regression model with an offset for the length of the risk period, with adjustment of time-varying factors (age and the use of other anti-diabetic agents [sulfonylureas, thiazolidinediones, dipeptidyl peptidase-4 inhibitors, GLP1 receptor agonists, and insulin])

Back to article page

Cardiovascular Diabetology

ISSN: 1475-2840